Effect of Pioglitazone on Abdominal Fat Distribution and Insulin Sensitivity in Type 2 Diabetic Patients

Cited by (726)

Items 601–700 of 726

1. ¿Es la grasa abdominal subcutánea un predictor de la variabilidad cardíaca en hombres con bajo riesgo metabólico?
   Universidad Pedagógica y Tecnológica de Colombia UPTC. Tunja, Boyacá., Angélica Avendaño V, Edgar A. Rodríguez M, Universidad Pedagógica y Tecnológica de Colombia UPTC. Tunja, Boyacá., Adriana Urbina, Universidad del Rosario. Bogotá DC. Colombia · 2016 · Salud UIS
2. The Glycemic, Cardiovascular and Hepatic Outcomes of Pioglitazone Treatment: Evidence for Its Increased Use
   Mayer B. Davidson · 2020
3. Type 2 Diabetes
   Ronald B Goldberg · 2006 · Fundamental and clinical cardiology
4. L’adipogenèse des tissus adipeux blancs : influence du microenvironnement
   Nathalie Boulet, David Estève, Anne Bouloumié, Jean Galitzky · 2013 · Obésité
5. Management of Type 2 Diabetes Mellitus: Is It Time for a Paradigm Shift?
   Kathleen Louise Wyne · 2004 · Metabolic Syndrome and Related Disorders
6. Combination therapy in type 2 diabetes mellitus
   Muhammad A Abdul‐Ghani, Ralph Anthony DeFronzo, Roy Eldor · 2015 · Wiley eBooks
7. Pioglitazona. Revisión de sus efectos metabólicos y sistémicos
   Á. Rodríguez Bernardino, Sonia Cebrián Blanco, Santiago Durán García · 2005 · Revista Clínica Española
8. Aging, Body Fat, and Carbohydrate Metabolism
   Marielisa Rincon, Radhika H. Muzumdar, Nir Barzilai · 2005 · Elsevier eBooks
9. WITHDRAWN: Reprint of: Thiazolidinediones for the treatment of type 2 diabetes
   J.W.F. Elte, Jean‐Frédéric Blickle · 2011 · European Journal of Internal Medicine · Retracted
10. The role of the gluteofemoral adipose tissue in cerebrovascular disease risk: evidence from a mendelian randomization and mediation analysis
    Evangelos Pavlos Myserlis, Marios K. Georgakis, Livia Parodi, Ernst Mayerhofer, Jonathan M. Rosand, Chirantan Banerjee, Christopher D. Anderson · 2024 · medRxiv
11. Alimentazione, salute e longevità nei pazienti adulti
    Guest Editors P. Gnerre, R Frediani, Roberto Risicato, Massimo Rondana, Roberto Nardi · 2019 · Italian Journal of Medicine
12. Olive Oil’s Attenuating Effects on Lipotoxicity
    Maamoun Basheer, Mariana Boulos, Areej Basheer, Arraf Loai, Nimer Assy · 2024 · Advances in experimental medicine and biology
13. Body composition as a potential biomarker of recurrence risk in patients with triple-negative breast cancer
    Jill B. De Vis, Cong Wang, Kirsten Nguyen, Lili Sun, Brigitte Jia, Alexander Dean Sherry, Mason Nicholas Alford-Holloway, Meridith L. Balbach, Tatsuki Koyama, A. Bapsi Chakravarthy et al. · 2025 · Breast Cancer Research and Treatment
14. Preclinical Evaluation of 2-Aminobenzothiazole Derivatives: In Silico, In Vitro, and Preliminary In Vivo Studies as Diabetic Treatments and Their Complications
    Natalia Reyes-Vallejo, Miguel Valdes, Adelfo Reyes‐Ramírez, Juan Andres Alvarado-Salazar, Alejandro Cruz, Erik Andrade‐Jorge, Jessica Elena Mendieta‐Wejebe · 2025 · Molecules
15. Resistant and Refractory Obesity: The Complexity of Anti-Obesity Therapy Failure
    Michał Nicze, Maciej Borówka, Adrianna Dec, Łukasz Bułdak, Aleksandra Bołdys, Bogusław Okopień · 2026 · International Journal of Molecular Sciences
16. Estrogen Mediates Capacity for Hyperplastic Adipose Expansion and Preserves Adipose Progenitor Cell Availability in Subcutaneous Depots of Female Mice
    Taylor B. Scheidl, Jessica L. Wager, Sophie Z. Yonan, Ji Soo Yoon, Elizabeth A. Wellberg, Jennifer Anne Thompson · 2026 · Diabetes
17. Combination of nateglinide with thiazolidinediones in Type 2 diabetes
    Christina Voulgari, Nikolaοs Tentolouris · 2009 · Expert Review of Endocrinology & Metabolism
18. Klinicheskiy sluchay primeneniya Pioglitazona pri steroidnom diabete u patsienta s bolezn'yu Itsenko-Kushinga
    E A Pigarova, L K Dzeranova, Gagik Radikovich Galstyan · 2005 · Obesity and metabolism
19. Comparison of the effects of long-term pioglitazone and rosiglitazone therapy on liver enzymes in type 2 diabetes
    Phey Ming Yeap, Khalida Ann Lockman, Rob A. Elton, Margaret Boyd, Peter Clive Hayes, Alan J. Jaap · 2011 · The British Journal of Diabetes
20. Diabetes and Heart Disease
    Burton E. Sobel · 2015 · Cardiovascular medicine
21. Dipeptidyl peptidase‐4 inhibitor lowers PPARγ agonist‐induced body weight gain by affecting food intake, fat mass and beige/brown fat but not fluid retention (1160.9)
    Yiling Fu, Takahiro Masuda, Akiko Eguchi, Jan Czogalla, Michael A. Rose, Alexander Kuczkowski, Maria Gerasimova, Ariel E. Feldstein, Miriam Scadeng, Volker Vallon · 2014 · The FASEB Journal
22. Non-Insulin Agents for Diabetes
    Gayatri Sreemantula, Santosh H Shankarnarayan · 2012
23. Long term effects of pioglitazone therapy with nonalcoholic steatohepatitis
    Haruo Nakayama, Shigetoshi Iwahasi, Toshiaki Ojima, Masao Kusano, Shigeyuki Asano, Yoshiki Sugai · 2009 · Kanzo
24. Rosiglitazone and Metformin in patients with type-2 Diabetes Mellitus who are inadequately controlled on Metformin alone
    Zafar U. Khan, Muhammad Adnan Iqbal, Muhammad Arif Nadeem, Sara Shoaib · 2016 · Annals of King Edward Medical University
25. A comparative Between the Effects of Glycyrrhiza glabra Roots Extract and Pioglitazone on Induced Poly Cystic Ovary Syndrome in Rats.
    Ali Ali, Huda F. Hasan · 2016 · Journals & Books Hosting (International Knowledge Sharing Platform)
26. Pharmacogenetic Aspects of Type 2 Diabetes Treatment
    N. O. Pozdnyakov, I. N. Kagarmanyan, A. E. Miroshnikov, Е. С. Емельянов, Груздева Анна Андреевна, А. М. Сироткина, I. A. Dukhanina, A. A. Milkina, A. A. Khokhlov, Поздняков Станислав Олегович · 2020 · Бюллетень Восточно-Сибирского научного центра Сибирского отделения Российской академии медицинских наук
27. Obesity and Type 2 Diabetes
    Sviatlana V. Zhyzhneuskaya, Roy Taylor · 2019 · Endocrinology
28. NAFLD, the hepatic manifestation of the metabolic syndrome
    Tirthankar Chaudhury, Lucia Brodosi, Giulio Marchesini, Sandip Kumar Mitra, Maria Letizia Petroni · 2024 · Elsevier eBooks
29. The Expanding Problem of Regional Adiposity: Revisiting a 1985 Diabetes Classic by Ohlson et al.
    Olga T. Gupta, Rana K. Gupta · 2024 · Diabetes
30. Non alcoholic fatty liver disease (NAFLD): an overview
    NC McAvoy, Ann Lockman, P.C. Hayes · 2007 · The Journal of the Royal College of Physicians of Edinburgh
31. New concepts in pathogenesis and management of polycystic ovarian syndrome: Insulin resistance and role of insulin sensitizers
    Rashmi Prasad Yadav · 1970 · Nepal Journal of Obstetrics and Gynaecology
32. EFFECT OF PIOGLITAZONE ON LIPID PROFILE IN TYPE 2 DIABETIC PATIENTS
    Amjad Mahboob, Amjad Taqweem, Intekhab Alam, Ibrar Ahmad, Zafar Ali, Muhammad Bilal · 2012 · Journal of Postgraduate Medical Institute
33. Effect of pioglitazone on body composition in Asian Indian diabetics suggest role of limb fat in their high insulin resistance.
    P. Mathur, S. Mathur, Poonam Punjabi, R. Vaishnav, M. Mathur · 2016 · Journal of Advances in Medicine and Medical Research
34. The effect of pioglitazone on performance and plasma lipids of post-peak female broiler breeders
    Mehdi Heidari Amale, Ahmad Zare Shahneh, M. Zaghari · 2019 · پژوهش های علوم دامی (دانش کشاورزی)
35. Hígado graso no alcohólico: certezas e incertidumbres de una epidemia silenciosa
    Esteban González Ballerga, Andrea Curia, Kenneth J. Cusi · 2020 · Acta gastroenteorológica latinoamericana/Acta gastroenterológica latinoamericana
36. Personalized Nutrition
    George Moschonis, Katherine Mary Livingstone, Jessica R. Biesiekierski · 2019 · MDPI eBooks
37. Fatty acid and glucose metabolism in upper body obesity : effects of diet and exercise compared to pioglitazone administration
    Samyah Shadid · 2007 · Research Publications (Maastricht University)
38. The HAART-Induced Metabolic Syndrome
    Sotirios Tsiodras, Theodoros Kelesidis, Christos Socrates Mantzoros · 2006 · Humana Press eBooks
39. Mécanismes de l’action antidiabétique des thiazolidinediones
    Bénédicte Gaborit, Fabrizio Andréelli · 2008 · Nutrition Clinique et Métabolisme
40. Two-year effect of rosiglitazone in chinese poorly controlled type 2 diabetic patients.
    Jenn‐Kuen Lee, Chih-Hsun Chu, Ming-Ju Chuang, Shiu-Chu Lin, Mei-Chun Wang, Chih-Chen Lu, Chun-Chin Sun, Hing‐Chung Lam · 2006 · PubMed
41. Hypolipidemic Effects and Mechanisms of Val-Phe-Val-Arg-Asn in C57BL/6J Mice and 3T3-L1 Cell Models
    Shi Wei, Hui He, Cao Ruge, Tao Hou · 2019 · Preprints.org
42. Subcutanous Fat Accumulation and Thiazolidinedione Derivatives : Sex Differences and Their Relation to Glycemic Control (Original)
    Mori, Yutaka, Hideaki Komiya, Naoyuki Kurokawa, Tajima, Naoko · 2003 · The Academic Repository of The Jikei University School of Medicine (Jikei University School of Medicine)
43. Der metabolische Einfluss von Zigarettenrauchkondensat auf die Wirkung von Glitazonen und Sartanen bei 3T3-L1-Präadipozyten
    Irina Heinz · 2013
44. PPAR agonists in the treatment of diabetes
    Sunder Raj D. Mudaliar, Robert R. Henry · 2015
45. Proteomic, transcriptomic and epidemiological analysis of adipocyte-secreted proteins'towards a system biological understanding of adipocytes
    P. Wang · 2007 · Research Publications (Maastricht University)
46. Chapter 6 The adipocyte and adipose tissue as endocrine organs: Impact on the insulin resistance phenotype
    Robert R. Henry, Susan A. Phillips, Sunder Raj D. Mudaliar, Theodore P. Ciaraldi · 2006 · Advances in molecular and cellular endocrinology
47. Tratamento com troglitazona aumenta as reservas de glicogênio de músculos desnervados
    Carlos Alberto da Silva · 2006 · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
48. Peroxisome Proliferator‐Activated Receptor γ Modulation for the Treatment of Type 2 Diabetes
    Alan M. Warshawsky, Anne Reifel Miller · 2008 · Methods and principles in medicinal chemistry
49. Thiazolidinediones: a long way to clinical practice
    A A Aleksandrov, Svetlana Semenovna Kukharenko, М. Н. Ядрихинская, Olga Alexandrovna Shatskaya, Е Н Дроздова · 2011 · Problems of Endocrinology
50. Treatment of the Obese Patients With Type 2 Diabetes
    Jean Lin Chan, Christos Socrates Mantzoros, Martin J. Abrahamson · 2006 · Humana Press eBooks
51. ピオグリタゾン投与5年間の体重推移の検討 : JDDMによる多施設共同研究-(JDDM24)
    小森 克俊, 文宣 奥口, 金塚 東, 小林 正, 糖尿病データマネジメント研究会 · 2013 · 糖尿病
52. Effect of the ligands of thyroid hormone receptor on non-alcoholic fatty liver disease
    Marta Anna Kowalik · 2009 · VEprints - Universita degli Studi di Cagliari
53. Evidence of mature adipocyte proliferation regulated by proliferin
    Kazuo Kajita, Ichiro Mori, Takayuki Hanamoto, Zhiliang Wu, Takahide Ikeda, Kei Fujioka, Masahiro Yamauchi, Hideyuki Okada, Aki Minami, Toshiko Kajita et al. · 2010 · Nature Precedings
54. Type 2 diabetes in obese adolescents: pathophysiology and treatment
    Grace J. Kim, Sonia Caprio · 2015 · Wiley eBooks
55. Effektivnost' i bezopasnost' pioglitazona (Aktos?) v kachestve monoterapii i v kombinatsii s glibenklamidom ili metforminom u patsientov s sakharnym diabetom tipa 2
    Marina Vladimirovna Shestakova, Mikhail Ivanovich Balabolkin, Mikhail Borisovich Antsiferov, Alexander Yur'evich Mayorov, Lyudmila Alexandrovna Chugunova, Минара Шамхаловна Шамхалова, N N Brevnova, I. Naumenkova, N. V. Zaytseva, Л. В. Цибина et al. · 2005 · Diabetes Mellitus
56. PPAR-gamma agonisti nella terapia del diabete mellito e di altre malattie endocrino-metaboliche
    Francesco Giorgino, Luigi Laviola · 2005 · L Endocrinologo
57. Prise de poids et traitements antidiabétiques
    Bruno L Vergès · 2008 · Médecine des Maladies Métaboliques
58. Nealkogol'naya zhirovaya bolezn' pecheni: aktual'nye proekty
    С А Бутрова, A Yu Eliseeva · 2007 · Obesity and metabolism
59. Prospective study (Manda study 1) on the clinical effects of pioglitazone in relation to gender differences in Japanese patients with type 2 diabetes
    Shinji Taneda, Hidenori Bando, Kazushi Misawa, Kennichi Tuchida, Yuko Akimoto, Tomoyasu Nawa, Seiya Hagiwara, Minoru Kikuchi, Toshiaki Sasaki, Toshi Niizuma et al. · 2013 · Diabetology International
60. Pioglitazone-Metformin Extended-Release Fixed-Dose Combination for the Treatment of Type 2 Diabetes
    Jochen Seufert · 2010 · Clinical Medicine Reviews in Vascular Health
61. Economic benefits of pioglitazone for treating patients with Type 2 diabetes
    Loren David Grossman, Christopher J. Longo · 2004 · Expert Review of Pharmacoeconomics & Outcomes Research
62. Clinical and Economic Evaluation of Two Thiazolidinediones in the Management of Diabetes
    Fadia Tohme Shaya, Stacy Calloway, Pharmd C, Antoine C. El Khoury, Josette Tomety, Pharmd C · 2015
63. A molecular approach to insulin signalling and caveolae in primary adipocytes
    Karin G. Stenkula · 2007 · DiVA (Linkoping University)
64. Pioglitazone for patients with type 2 diabetes and nonalcoholic steatohepatitis
    Janet C. King, Kris V. Kowdley · 2007 · Hepatology
65. IMPACT OF CURRENT DIABETES THERAPIES ON MACROVASCULAR OUTCOMES
    Carol Wysham · 2006
66. Efeito da dermolipectomia na sensibilidade à insulina em mulheres obesas, em fase de estabilidade de peso, após cirurgia bariátrica
    Vyvianne Azoubel Roizenblatt · 2009
67. The impact of obesity and chronic PPAR Alpha agonist treatment on cardiac function, metabolism and ischaemic tolerance
    Wayne T Smith · 2012 · SUNScholar (Stellenbosch University)
68. On the importance of fat cell size, location and signaling in insulin resistance
    Niclas Franck · 2009 · KTH Publication Database DiVA (KTH Royal Institute of Technology)
69. Pioglitazone and Nonalcoholic Steatohepatitis
    Guenther H. Boden · 2007 · Current Diabetes Reports
70. Effect of Pioglitazone on Body Fat and Intramuscular Fat Accumulation in Otsuka Long- Evans Tokushima Fatty Rats : Its Relation to the Expression of Tumor Necrosis Factor-alpha mRNA (Original)
    Mori, Yutaka, Hideaki Komiya, Naoyuki Kurokawa, Tajima, Naoko · 2003 · The Academic Repository of The Jikei University School of Medicine (Jikei University School of Medicine)
71. IS THERE AN INTRINSIC VASCULAR BENEFIT TO TZDs? EXAMINING THE EVIDENCE *
    Bartol Tg, Thomas G. Bartol, Carol Wysham, Kathleen Murphy White · 2006
72. Biochemical Effects of Some Peroxisome Proliferator Activated Receptor Ligands in Hyperhomocysteinemic-rats
    Ghada M. Al‐Ashmawy, Hoda A. El‐Bahrawy, Nahla E. El‐Ashmawy · 2013 · Journal of Applied Pharmaceutical Science
73. Adverse effect of pioglitazone in military personnel and their families: a preliminary report.
    Thishnapha Vudhironarit, Yupin Benjasuratwong, Supen Patarakitvanit, Supatta Temboonkiat, Nisamanee Satyapan · 2009 · PubMed
74. STUDY OF THE EFFECTS OF PIOGLITAZONE MONOTHERAPY IN NEWLY DIAGNOSED PATIENTS OF TYPE 2 DIABETES MELLITUS
    Neelesh Arya, Ashutosh Chourishi, Subodh Pandey · 2012
75. Treatment with Thiazolidinediones
    Seda Suvag, Kristina M. Utzschneider, Steven E. Kahn · 2013 · Springer eBooks
76. The Effects of Growth Hormone and Insulin-Like Growth Factor-1 Treatments on Hepatic Gene Expression in Obese and Diabetic Mice with Nonalcoholic Fatty Liver Disease
    John Blischak · 2010 · OhioLink ETD Center (Ohio Library and Information Network)
77. Assessment and Treatment of Impaired Insulin- Secretion and Action in Type 2 Diabetes
    Mozhgan Dorkhan · 2008 · Lund University Publications (Lund University)
78. Avaliação do perfil de expressão gênica modulado pelo GQ-16 em adipócitos 3T3-L1 utilizando a técnica de microarranjo
    Flora Aparecida Milton · 2015 · RIUnB Institutional Repository (University of Brasília)
79. Pioglitazone therapy could improve histology of a lean patient with advanced nonalcoholic steatohepatitis. A case report
    Haruo Nakayama, Shiniti Ikeya, Daisuke Okamoto, Daisuke Komazawa, Takayuki Watanabe, Hiromiti Itou, Masanori Tosa, Naohiro Dairaku, Toshiyuki Ikeda, Seiiti Takahashi et al. · 2014 · Kanzo
80. ReviewArticle PPARδ Agonism for the Treatment of Obesity and Associated Disorders: Challenges and Opportunities
    David V. Erbe, James F. Tobin · 2008
81. Editorial NASH and thiazolidinediones: Not to be taken lightly q
    Jean-François Dufour · 2007
82. ApproachtoTherap y in Patients With Newly Diagnosed Type 2 Diabetes
    Ralph Anthony DeFronzo, Roy Eldor · 2013
83. Effects of nutrients and exercise on skeletal muscle and adipose tissue
    Merethe H. Rokling-Andersen · 2009 · NORA - Norwegian Open Research Archives
84. Insulin resistance in diabetes
    Ravikumar Balasubramanian, Roy Taylor · 2004 · CRC Press eBooks
85. Efeito do GQ-02, derivado de tiazolidinadionas, sobre a aquisição de fenótipo termogênico pelo adipócito in vivo e em cultura de células
    Camila Greice Christ · 2016
86. Bioprospecting for hypoglycemic activities and safety of selected traditionally used plants in the management of diabetes mellitus
    Wycliffe Arika Makori · 2016 · Kenyatta University Institutional Repository (Kenyatta University)
87. LMNA (Lamin A/C), PPARγ遺伝子に変異を認めず感音性難聴，成長障害を認めるKöbberling型の先天性部分型リポジストロフィーの長期観察例
    佐々木 悠, 久美子 大久保, 冨永博之, 富田 健一, 飯野 研三, 田尻祐司, Hiroshi Maegawa, 柏木 厚典, 小野 順子, 秋三 熊谷 et al. · 2008 · 糖尿病
88. Fermented Soy Product Isoflavone Composition, and Role in Gene Responses in C57BL/6 Mice
    Gayle E. Shrode · 2010 · OhioLink ETD Center (Ohio Library and Information Network)
89. Atividade de novos derivados de tiazolidinodionas sobre a diferenciação de pré-osteoblastos e pré-adipócitos
    Cristiane Akemi Iamamoto Saito · 2015
90. mTOR complexo 1 atenua a resposta pró-inflamatória de macrófagos e inflamação do tecido adiposo associadas à obesidade.
    Vivian A. Paschoal · 2016 · Digital Library of Theses and Dissertations (Universidade de São Paulo)
91. Treatment with Oral Drugs
    Cristina Bianchi, Giuseppe Daniele, Angela Dardano, Stefano Del Prato · 2018 · Endocrinology
92. The Role of Pik3r1 in the Regulation of Adipose Tissue Insulin Sensitivity
    Zachary Stephen Clayton · 2018 · Scholars' Bank (University of Oregon)
93. New pharmacological approaches in type 2 diabetes mellitus
    Kenneth J. Cusi · 2009 · Dialnet (Universidad de la Rioja)
94. mTORC1 é um importante mediador do aumento de adiponectina sérica e do metabolismo de BCAA no tecido adiposo induzido pela rosiglitazona.
    Maynara Lucca Andrade · 2019 · Digital Library of Theses and Dissertations (Universidade de São Paulo)
95. Adipose tissue developmental growth constraints uncouple fat distribution from glucose metabolism in two mouse models of obesity
    Zachary L. Sebo, CHRISTOPHER D. CHURCH, Ryan Berry, Matthew S. Rodeheffer · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
96. Analysis of Anthropometric Measurements Using Receiver Operating Characteristic Curve for Impaired Waist to Height Ratio Detection
    Érika Severeyn, Alexandra La Cruz, Sara Wong, Gilberto Perpiñán · 2020 · Advances in intelligent systems and computing
97. Pre-diabetes linked microRNA miR-193b-3p targets PPARGC1A and increases lipid accumulation in hepatocytes: potential biomarker of fatty liver disease
    Inês G. Mollet, Maria Paula Macedo · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
98. Defining Your Shape
    Nathan Denton · 2021 · Oxford University Press eBooks
99. Choosing Medications for Weight Loss in Type 2 Diabetes Mellitus
    Shubhada M. Jagasia, Chase Dean Hendrickson, Alexander Jonathan Williams · 2021 · Wiley eBooks
100. Ectopic Fat and the Metabolic Syndrome
     Frederico G. S. Toledo, David E. Kelley · 2007 · Springer eBooks